argenx SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Karen Massey
- Full Time Employees
- 1,863
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101EB
- IPO Date
- May 18, 2017
- CIK
- 0001697862
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE, a commercial-stage global immunology company, develops and commercializes differentiated antibody-based therapies targeting severe autoimmune diseases using its proprietary Immunology Innovation Program and SIMPLE Antibody platform; its lead product VYVGART (efgartigimod) is an FcRn blocker approved for generalized myasthenia gravis in the United States, Europe, Japan, Israel, Canada and Mainland China, as well as for chronic inflammatory demyelinating polyneuropathy, with subcutaneous formulations including pre-filled syringes launched to enhance patient access and ongoing label expansions into broader myasthenia gravis populations such as seronegative, pediatric and ocular via studies like ADAPT-SERON, ADAPT-JR and ADAPT-OCULUS; the pipeline features advancing candidates like ARGX-213 targeting FcRn, ARGX-121 for IgA, ARGX-109 for IL-6 and ARGX-220 as a novel sweeping antibody, alongside earlier programs and out-licensed assets including LP0145 (ARGX-112) to LEO Pharma for atopic dermatitis, AGMB-101 (ARGX-114) to AgomAb Therapeutics for fibrotic diseases and ARGX-115 (ABBV-151) to AbbVie for oncology. argenx SE operates in key markets including the United States, Europe, Japan and Greater China through partnerships such as with Zai Lab; it was founded in 2008 in Ghent, Belgium by Tim van Hauwermeiren, Hans de Haard and Torsten Dreier, with headquarters in Amsterdam, Netherlands, and maintains subsidiaries like argenx BV in the Netherlands, argenx SAS in France and argenx UK Ltd. Recent developments include expansion of VYVGART into immune thrombocytopenia and multifocal motor neuropathy via registrational programs like ADVANCE and EMPASSION with topline data anticipated, autoinjector development for 2027 launch, four new pipeline nominations through the Immunology Innovation Program in 2025, sustained R&D investment supported by approximately EUR 2.6 billion in cash equivalents as of late 2024, and global commercial infrastructure growth alongside strategic collaborations leveraging technologies like Halozyme's subcutaneous delivery.
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
argenx SE (ARGX) M&A Call Transcript
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx to buy Forte Biosciences for about $2.2 billion
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
argenx: Vyvgart Is Taking Off (Rating Upgrade)
argenx SE (ARGX) Q2 2026 Earnings Call Transcript
argenex Q2 Earnings Call Highlights
Argenx's Vyvgart sales jump in second quarter
Boston Common Asset Management LLC Takes Position in argenex SE $ARGX
Artisan Mid Cap Fund Q2 2026 Performance Review
Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs